2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

603. Lymphoid Oncogenesis: Basic: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Omics Technologies, Bioinformatics, Gene Editing, Treatment Considerations, Combination Therapy, Drug Development, Biological Processes, Apoptosis, Pathogenesis, Genomics, Metabolism, Molecular Biology, Multi-Systemic Interactions, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Study Population, Human, Animal Model
PAPER

4980 SWI/SNF remodeling complexes control CTCF function and 3D genome architecture to regulate lymphoma proliferation

Sonia Debek, PhD, Cem Meydan2, Christopher Chin3, Ioanna Tsialta, MS4, Benedikt Pelzer, MD5, Ceyda Durmaz6, Arnold Ou7, Constance Maurer8, Alejandra Laguillo-Diego9, Laurianne Scourzic, PhD10, Jiali Yu11, Sravya Tumuluru, PhD12, Rui Wu13, Brian Darsow14, Jose Luis Marin Rubio15, Matthias Stadtfeld, PhD16, Eftychia Apostolou17, Christopher Mason18, Kojo Elenitoba-Johnson, MD19, Viviana Risca20, Ari Melnick, MD21, Darko Barisic, PhD22
1 Weill Cornell Medicine, New York, New York, United States
2 Weill Cornell Medicine, New York, New York, United States
3 Weill Cornell Medicine, New York, New York, United States
4 Icahn School of Medicine at Mount Sinai, New York, New York, United States, Weill Cornell Medicine, New York, New York, United States
5 Essen University Hospital, Essen, Germany, Weill Cornell Medicine, New York, New York, United States
6 Weill Cornell Medicine, New York, New York, United States
7 The Rockefeller University, New York, New York, United States
8 Queen Mary University of London, London, United Kingdom
9 Weill Cornell Medicine, New York, New York, United States
10 Weill Cornell Medicine, New York, New York, United States
11 Weill Cornell Medicine, New York, New York, United States
12 Weill Cornell Medicine, New York, New York, United States
13 Memorial Sloan Kettering Cancer Center, New York, New York, United States
14 Hunter College, New York, New York, United States
15 Memorial Sloan Kettering Cancer Center, New York, New York, United States
16 Weill Cornell Medicine, New York, New York, United States
17 Weill Cornell Medicine, New York, New York, United States
18 Weill Cornell Medicine, New York, New York, United States
19 Memorial Sloan Kettering Cancer Center, New York, New York, United States
20 The Rockefeller University, New York, New York, United States
21 Josep Carreras Leukaemia Research Institute, Badalona, Spain, Weill Cornell Medicine, New York, New York, United States
22 Weill Cornell Medicine, New York, New York, United States

Background: BAF (mSWI/SNF) subunits are inactivated in roughly 20% of cancers, with ARID1A being the most frequently mutated subunit, including more than 35% of diffuse large B-cell lymphomas and 10-15% of follicular lymphomas. BAF assembles into three complexes defined by specific subunits: canonical BAF (cBAF; ARID1A), polybromo BAF (PBAF; PBRM1 and ARID2) and non-canonical BAF (ncBAF; BRD9). All three share the SMARCA4/2 ATPase but occupy distinct chromatin regions. BAF deficiency is usually attributed to lost accessibility at lineage enhancers, which does not explain why BAF mutations converge across tissues, particularly distinct subsets of blood cancers. We asked whether cBAF complex deficiency instead converges on one chromatin defect common to diverse cell types.

Methods: We profiled chromatin accessibility (ATAC-seq) in 15 human cell lines treated with the SMARCA2/4 inhibitor FHD-286 and in 6 isogenic ARID1A-deficient lines, and performed CTCF, SMC3, ARID1A, PBRM1 and BRD7 chromatin immunoprecipitation (ChIP-seq), chromatin conformation capture with Micro-C, CTCF and PBRM1 immunoprecipitation-mass spectrometry (IP-MS), and single-cell multiome in lymphoma cells. Function was tested with CRISPR deletion of CTCF, ARID2 or SMARCA5; ARID1A-FKBP12 degron; and conditional knockout of Arid1a, Ctcf or Pbrm1 in mouse lymphocytes, and Fucci2a mice. Readouts included germinal center immunophenotyping, proliferation tests, cell cycle assays and PacBio whole-genome sequencing (WGS).

Results: Chromatin opened at CTCF motifs in 20 of 21 lines, with the largest gains in lymphoid and myeloid cells, whereas closing peaks were lineage-specific, making CTCF gain the one cell-context independent consequence of BAF loss. CTCF together with cohesin complex establish 3D genome architecture. Consistently, CTCF and SMC3 (cohesin) occupancy increased at newly accessible sites. CRISPR CTCF depletion reversed 93.5% of ARID1A-driven gains, and accessibility rose within 4h of FHD-286 and 6h of ARID1A degron depletion, establishing direct antagonism. Micro-C showed 3D chromatin domain splitting, stronger boundary insulation and increase of promoter-proximal loops at gained CTCF sites, with genes in strengthened domains upregulated. CTCF IP-MS recovered every PBAF-specific subunit with enrichment comparable to that of known CTCF interactors (ISWI complex with SMARCA5 subunit), while cBAF- and ncBAF-specific subunits were depleted, documenting for the first time the interaction between CTCF and PBAF. ARID1A loss increased proliferation of lymphoma cells (p=0.0054), while deletion of ARID2 or SMARCA5 eliminated this proliferation gain (ARID2 KO: p<0.0001; SMARCA5 KO: p=5.0e-06), placing PBAF and ISWI downstream of cBAF loss as effectors. CTCF overexpression alone phenocopied the ARID1A-Het growth advantage in vitro. Pan-cancer analysis of survival data showed that patients with both ARID1A and CTCF alterations survived longer than those with a mutation ARID1A alone (p=4.672e-5). In vivo, Arid1a heterozygosity expanded the germinal center dark zone, and Ctcf or Pbrm1 heterozygosity fully restored dark zone to light zone balance (Ctcf: p=0.0005; Pbrm1: p=0.0009), indicating that excess CTCF locks these cells in the proliferative dark zone. In the VavP-Bcl2;Arid1a-Het lymphomagenesis cohort, accessibility gain at CTCF sites was the earliest chromatin change, present before disease onset and continued throughout lymphoma progression. As cohesin also governs chromosome segregation, we asked whether excess CTCF/cohesin occupancy extends its effects into mitosis. cBAF-deficient cells accumulated in G2/M, 20% failed to exit mitosis 6h after nocodazole release. Long-read WGS found excess structural variants, with 28% of breakpoints at CTCF-gained sites versus 12-13% elsewhere (p=2.2e-16). Fucci2a-sorted germinal center B cells confirmed that CTCF gain after ARID1A loss is restricted to S and M phase.

Conclusions: cBAF restrains CTCF and cohesin genome-wide, and its loss rewires those sites to gain PBAF and ISWI. The resulting CTCF gain of function subdivides 3D chromatin domains, shortens enhancer-promoter loops, expands the dark zone and persists into S and M phase, where gained CTCF likely delays mitotic exit and marks sites of structural breakage. This axis accounts for both the transcriptional and the genomic instability phenotypes of ARID1A-mutant lymphoma and identifies CTCF and PBAF as candidate dependencies in BAF-mutant B-cell malignancies.
Sonia Debek, PhD: No relevant conflicts of interest to declare.